Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 1040377-02-3 | MDL No. : | MFCD11505042 |
Formula : | C8H11BrN2O | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | WRDSDCYKWVXMRY-UHFFFAOYSA-N |
M.W : | 231.09 | Pubchem ID : | 51063926 |
Synonyms : |
|
Num. heavy atoms : | 12 |
Num. arom. heavy atoms : | 5 |
Fraction Csp3 : | 0.62 |
Num. rotatable bonds : | 1 |
Num. H-bond acceptors : | 2.0 |
Num. H-bond donors : | 0.0 |
Molar Refractivity : | 49.39 |
TPSA : | 27.05 Ų |
GI absorption : | High |
BBB permeant : | Yes |
P-gp substrate : | Yes |
CYP1A2 inhibitor : | Yes |
CYP2C19 inhibitor : | No |
CYP2C9 inhibitor : | No |
CYP2D6 inhibitor : | No |
CYP3A4 inhibitor : | No |
Log Kp (skin permeation) : | -6.84 cm/s |
Log Po/w (iLOGP) : | 2.21 |
Log Po/w (XLOGP3) : | 1.23 |
Log Po/w (WLOGP) : | 2.0 |
Log Po/w (MLOGP) : | 1.27 |
Log Po/w (SILICOS-IT) : | 1.73 |
Consensus Log Po/w : | 1.69 |
Lipinski : | 0.0 |
Ghose : | None |
Veber : | 0.0 |
Egan : | 0.0 |
Muegge : | 0.0 |
Bioavailability Score : | 0.55 |
Log S (ESOL) : | -2.29 |
Solubility : | 1.19 mg/ml ; 0.00513 mol/l |
Class : | Soluble |
Log S (Ali) : | -1.4 |
Solubility : | 9.29 mg/ml ; 0.0402 mol/l |
Class : | Very soluble |
Log S (SILICOS-IT) : | -2.17 |
Solubility : | 1.57 mg/ml ; 0.00681 mol/l |
Class : | Soluble |
PAINS : | 0.0 alert |
Brenk : | 0.0 alert |
Leadlikeness : | 1.0 |
Synthetic accessibility : | 2.03 |
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P261-P305+P351+P338 | UN#: | N/A |
Hazard Statements: | H302-H315-H319-H335 | Packing Group: | N/A |
GHS Pictogram: |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
68% | With dichloro(1,1'-bis(diphenylphosphanyl)ferrocene)palladium(II)*CH2Cl2; potassium acetate In N,N-dimethyl-formamide at 80℃; for 10 h; Inert atmosphere | To a solution of 4-bromo-1-(oxan-4-yl)-1H-pyrazole (1.0 g, 4.33 mmol) and 4,4,5,5-tetramethyl-2-(tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane 38 (1.32 g, 5.19 mmol) in 10 ml of DMF was added potassium acetate (1.27 g, 12.98 mmol), followed by 1,1'-Bis(diphenylphosphino)ferrocene-palladium(II)dichloride dichloromethane complex (177 mg, 0.22 mmol) under argon. The resulting mixture was stirred at 80 0C for 10 h and then diluted with 40 ml of water. The mixture was extracted with EA (30 ml × 3). The combined organic phase was washed with water (30 ml × 3), brine, dried over anhydrous Na2SO4 and concentrated under vacuum. The crude product was purified by silica gel column chromatography (EA/PE, 1/4) to afford 39 as a white solid in 68percent yield. NMR (300 MHz, CDCl3) δ 7.80 (s, 1H), 7.75 (s, 1H), 4.42-4.31 (m, 1H), 4.12-4.07 (m, 2H), 3.57-3.49 (m, 2H), 2.13-1.99 (m, 4H), 1.32 (s, 12H). |
68% | With dichloro(1,1'-bis(diphenylphosphanyl)ferrocene)palladium(II)*CH2Cl2; potassium acetate In N,N-dimethyl-formamide at 80℃; for 10 h; Inert atmosphere | To a solution of 4-bromo-1-(oxan-4-yl)-1H-pyrazole 26a (1.00 g, 4.33 mmol) and 4,4,5,5-tetramethyl-2-(tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane (1.32 g, 5.19 mmol) in 10 mL of DMF was added potassium acetate (1.27 g, 12.98 mmol), followed by 1,1'-bis(diphenylphosphino)ferrocene-palladium(II)dichloride dichloromethane complex (177 mg, 0.22 mmol) under argon. The resulting mixture was stirred at 80 °C for 10 h and then diluted with 40 mL of water. The mixture was extracted with EA (3 × 30 mL). The combined organic phase was washed with water (3 × 30 mL), brine, dried over anhydrous Na2SO4 and concentrated under vacuum. The crude product was purified by silica gel column chromatography (EA/PE, 1:4) to afford 25c as white solid in 68percent yield. 1H NMR (300 MHz, CDCl3) δ 7.80 (s, 1H), 7.75 (s, 1H), 4.42-4.31 (m, 1H), 4.12-4.07 (m, 2H), 3.57-3.49 (m, 2H), 2.13-1.99 (m, 4H), 1.32 (s, 12H). |
19% | With (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride; potassium acetate In dimethyl sulfoxide at 90℃; | C. To a solution of 4-bromo-l-(tetrahydro-2H-pyran-4-yl)-lH- pyrazole (2.90 g, 12.6 mmol) in dimethyl sulfoxide (25 mL) was added potassium acetate (4.94 g, 50.4 mmol), 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-l,3,2- dioxaborolan-2-yl)-l,3,2-dioxaborolane (6.40 g, 25.2 mmol). The mixture was degassed for 10 min, and then [l, -bis(diphenylphosphino)ferrocene]dichloro-palladium(II) (0.922 g, 1.26 mmol) was added. The mixture was degassed for another 10 minutes and heated at 90 °C overnight, diluted with ethyl acetate (80 mL), washed with water (2 x 20 mL), brine (20 mL), dried and filtered. The solvent of the filtrate was removed and the residue was purified by flash column chromatography eluted with 20percent ethyl acetate in hexanes to afford l-(tetrahydro-2H-pyran-4-yl)-4-(4,4,5,5-tetramethyl-l,3,2- dioxaborolan-2-yl)-lH-pyrazole (0.66 g, 19percent) as a white solid. 1H NMR (400 Hz, CDCls) δ 7.81 (s, 1H), 7.76 (s, 1H), 4.42-4.32 (m, 1H), 4.14-4.06 (m, 2H), 3.58-3.50 (m, 2H), 2.16-1.98 (m, 4H), 1.32 (s, 12H). |
[ 1040377-07-8 ]
4-Bromo-1-(tetrahydrofuran-3-yl)-1H-pyrazole
Similarity: 0.90
[ 1563531-47-4 ]
4-Bromo-3-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazole
Similarity: 0.83
[ 1012880-01-1 ]
4-Bromo-1-cyclopentyl-1H-pyrazole
Similarity: 0.82
[ 925180-06-9 ]
4-Bromo-1-(3-hydroxypropyl)pyrazole
Similarity: 0.79
[ 1040377-07-8 ]
4-Bromo-1-(tetrahydrofuran-3-yl)-1H-pyrazole
Similarity: 0.90
[ 1563531-47-4 ]
4-Bromo-3-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazole
Similarity: 0.83
[ 1012880-01-1 ]
4-Bromo-1-cyclopentyl-1H-pyrazole
Similarity: 0.82
[ 1598643-02-7 ]
1-(Tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-ol
Similarity: 0.81
[ 1190380-49-4 ]
1-(Tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-amine
Similarity: 0.81
[ 1563531-47-4 ]
4-Bromo-3-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazole
Similarity: 0.83
[ 1598643-02-7 ]
1-(Tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-ol
Similarity: 0.81
[ 1190380-49-4 ]
1-(Tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-amine
Similarity: 0.81
[ 1339665-24-5 ]
4-Bromo-3,5-dimethyl-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazole
Similarity: 0.78
[ 82099-98-7 ]
4-Bromo-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole
Similarity: 0.74